T1	PROC 46 78	Estudio para evaluar la eficacia
T2	CHEM 110 148	Plasma Rico en Factores de Crecimiento
T3	ANAT 156 173	superficie ocular
#1	AnnotatorNotes T3	C4321570; Surface of eye; Body Location or Region
T4	DISO 191 199	glaucoma
#2	AnnotatorNotes T4	C0017601; Glaucoma; Disease or Syndrome
T5	CHEM 230 251	fármacos hipotensores
T6	ANAT 252 260	oculares
#3	AnnotatorNotes T6	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T7	PROC 283 308	Evaluación de la eficacia
#4	AnnotatorNotes T7	C1707887; Efficacy Study; Research Activity
T8	CHEM 340 378	Plasma Rico en Factores de Crecimiento
T9	ANAT 386 403	superficie ocular
#5	AnnotatorNotes T9	C4321570; Surface of eye; Body Location or Region
T10	DISO 417 430	glaucomatosos
#6	AnnotatorNotes T10	C0017601; Glaucoma; Disease or Syndrome
T11	CHEM 461 482	fármacos hipotensores
T12	ANAT 483 491	oculares
#7	AnnotatorNotes T12	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T13	DISO 515 523	Glaucoma
#8	AnnotatorNotes T13	C0017601; Glaucoma; Disease or Syndrome
T14	PROC 579 593	diagnosticados
#9	AnnotatorNotes T14	C0011900; Diagnosis; Diagnostic Procedure
T15	DISO 597 605	glaucoma
#10	AnnotatorNotes T15	C0017601; Glaucoma; Disease or Syndrome
T16	PROC 627 638	tratamiento
#11	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	CHEM 659 680	fármacos hipotensores
T18	ANAT 681 689	oculares
#12	AnnotatorNotes T18	C0015392; Eye; Body Part, Organ, or Organ Component | C1280202; Entire eye; Body Part, Organ, or Organ Component
T19	CHEM 105 109	PRGF
T20	CHEM 708 720	conservantes
#13	AnnotatorNotes T20	C0033086; Pharmaceutical Preservatives; Biomedical or Dental Material
T21	ANAT 856 873	superficie ocular
#14	AnnotatorNotes T21	C4321570; Surface of eye; Body Location or Region
T22	DISO 886 895	toxicidad
#15	AnnotatorNotes T22	C0600688; Toxic effect; Injury or Poisoning
T23	CHEM 335 339	PRGF
T24	PROC 923 952	cirugías de superficie ocular
T25	ANAT 935 952	superficie ocular
#16	AnnotatorNotes T25	C4321570; Surface of eye; Body Location or Region
T26	PROC 962 974	tratamientos
#17	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	PROC 200 225	tratados de forma crónica
T28	DISO 1094 1118	acontecimientos adversos
#18	AnnotatorNotes T28	C0877248; Adverse event; Pathologic Function
T29	PROC 431 456	tratados de forma crónica
T30	PROC 774 788	consentimiento
#19	AnnotatorNotes T30	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T31	DISO 843 873	Patología de superficie ocular
T32	CHEM 900 921	fármacos hipotensores
T33	CHEM 979 992	hemoderivados
#20	AnnotatorNotes T33	C0456388; Blood product; Pharmacologic Substance | C1629497; Blood derivative; Pharmacologic Substance
T34	Date 13 17	2019
T35	LIVB 177 186	pacientes
#21	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	Duration 218 225	crónica
#22	AnnotatorNotes T36	C0205191; chronic; Temporal Concept
T37	LIVB 407 416	pacientes
#23	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T38	Duration 449 456	crónica
#24	AnnotatorNotes T38	C0205191; chronic; Temporal Concept
T39	LIVB 550 576	Pacientes  mayores de edad
#25	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T40	Age 561 576	mayores de edad
T41	Dose 691 698	3 gotas
T42	Frequency 698 702	/día
T43	Neg_cue 704 707	sin
T44	Duration 730 760	al menos, los dos últimos años
T45	Route 993 1000	tópicos
#26	AnnotatorNotes T45	C1522168; Topical Route of Drug Administration; Functional Concept
T46	Duration 1004 1023	los últimos 6 meses
T47	LIVB 1025 1047	mujeres en edad fértil
#27	AnnotatorNotes T47	C4324275; Woman of childbearing potential; Population Group
T48	Age 1036 1047	edad fértil
T50	LIVB 1083 1092	lactantes
#28	AnnotatorNotes T50	C4316174; Patients who are breastfeeding; Patient or Disabled Group
T53	Form 693 698	gotas
#29	AnnotatorNotes T53	C0015399; Eye Drops; Biomedical or Dental Material
T54	LIVB 1071 1080	gestantes
#30	AnnotatorNotes T54	C0033011; Pregnant Women; Population Group
T51	Neg_cue 874 885	diferente a
T49	PHYS 1058 1069	gestacional
#31	AnnotatorNotes T49	C0032961; Pregnancy; Organism Function
A1	Population_data T39 Age
A2	Assertion T20 Negated
A3	Assertion T22 Negated
A4	Population_data T47 Age
A5	Status T24 History_of
#32	AnnotatorNotes T1	C1707887; Efficacy Study; Research Activity 
#33	AnnotatorNotes T27	C0023977; Long-term care; Health Care Activity 
#34	AnnotatorNotes T29	C0023977; Long-term care; Health Care Activity 
#35	AnnotatorNotes T5	C0003364; Antihypertensive Agents; Pharmacologic Substance 
#36	AnnotatorNotes T11	C0003364; Antihypertensive Agents; Pharmacologic Substance 
#37	AnnotatorNotes T17	C0003364; Antihypertensive Agents; Pharmacologic Substance 
#38	AnnotatorNotes T32	C0003364; Antihypertensive Agents; Pharmacologic Substance 
R1	Has_Age Arg1:T39 Arg2:T40	
R2	Experiences Arg1:T39 Arg2:T15	
R3	Experiences Arg1:T39 Arg2:T16	
T52	Quantifier_or_Qualifier 644 658	mínimo con dos
R4	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T52	
R5	Location_of Arg1:T18 Arg2:T16	
R6	Used_for Arg1:T17 Arg2:T16	
R7	Location_of Arg1:T18 Arg2:T15	
R8	Has_Drug_Form Arg1:T17 Arg2:T53	
R9	Has_Dose_or_Strength Arg1:T17 Arg2:T41	
R10	Has_Frequency Arg1:T17 Arg2:T42	
R11	Negation Arg1:T43 Arg2:T20	
R12	Experiences Arg1:T39 Arg2:T20	
R13	Has_Duration_or_Interval Arg1:T17 Arg2:T44	
T55	Observation 791 815	participar en el estudio
#39	AnnotatorNotes T55	C1278516; Patient participation status; Finding
R14	Before Arg1:T30 Arg2:T55	
R16	Location_of Arg1:T21 Arg2:T31	
R17	Negation Arg1:T51 Arg2:T22	
R18	Causes Arg1:T32 Arg2:T22	
R19	Location_of Arg1:T25 Arg2:T24	
R20	Used_for Arg1:T33 Arg2:T26	
R21	Has_Route_or_Mode Arg1:T33 Arg2:T45	
R22	Overlap Arg1:T33 Arg2:T46	
R23	Has_Age Arg1:T47 Arg2:T48	
T56	Observation 1052 1069	deseo gestacional
#40	AnnotatorNotes T56	C0032992; Pregnancy, Planned; Finding
R24	Before Arg1:T56 Arg2:T49	
R25	Experiences Arg1:T47 Arg2:T56	
R26	Experiences Arg1:T54 Arg2:T49	
T57	Quantifier_or_Qualifier 1119 1125	graves
#41	AnnotatorNotes T57	C1547227; Severe - Severity of Illness Code; Intellectual Product
R27	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T57	
T58	PROC 1137 1144	estudio
#42	AnnotatorNotes T58	C0008976; Clinical Trials; Research Activity
R28	Overlap Arg1:T28 Arg2:T58	
R29	Location_of Arg1:T6 Arg2:T27	
R30	Location_of Arg1:T3 Arg2:T2	
R31	Location_of Arg1:T3 Arg2:T19	
R32	Location_of Arg1:T9 Arg2:T8	
R33	Location_of Arg1:T9 Arg2:T23	
R34	Experiences Arg1:T35 Arg2:T19	
R35	Experiences Arg1:T35 Arg2:T2	
R36	Experiences Arg1:T35 Arg2:T4	
R37	Experiences Arg1:T35 Arg2:T27	
R38	Has_Duration_or_Interval Arg1:T5 Arg2:T36	
R39	Used_for Arg1:T5 Arg2:T27	
R40	Location_of Arg1:T12 Arg2:T29	
R41	Used_for Arg1:T11 Arg2:T29	
R42	Experiences Arg1:T37 Arg2:T10	
R43	Experiences Arg1:T37 Arg2:T29	
R44	Experiences Arg1:T37 Arg2:T23	
R45	Experiences Arg1:T37 Arg2:T8	
R46	Location_of Arg1:T12 Arg2:T10	
R47	Location_of Arg1:T6 Arg2:T4	
R48	Has_Duration_or_Interval Arg1:T11 Arg2:T38	
R15	Before Arg1:T16 Arg2:T55	
R49	Overlap Arg1:T31 Arg2:T22	
#43	AnnotatorNotes T31	C1557335; Ocular surface disease; Disease or Syndrome
A6	Experiencer T50 Patient
A7	Experiencer T54 Patient
A8	Experiencer T47 Patient
A9	Experiencer T35 Patient
A10	Experiencer T37 Patient
A11	Experiencer T39 Patient
A12	Status T49 Future
